Grey Wolf Health (WOLF) 주식 개요는 캐나다에서 동물 건강 및 웰니스 회사로 운영되고 있습니다. 자세히 보기WOLF 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적5/6재무 건전성2/6배당0/6강점공정 가치 추정치보다 낮은 22.8% 에서 거래지난 1년간 수익이 192.9% 증가했습니다.위험 분석이자 지급액이 수익으로 잘 충당되지 않음의미 있는 시가총액이 없습니다(CA$60M)모든 위험 점검 보기WOLF Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$1.7544.6% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m37m2016201920222025202620282031Revenue CA$36.6mEarnings CA$1.8mAdvancedSet Fair ValueView all narrativesGrey Wolf Health Corp. 경쟁사CareRxSymbol: TSX:CRRXMarket cap: CA$217.0mCLS Holdings USASymbol: CNSX:CLSHMarket cap: CA$5.9mSucroSymbol: TSXV:SUGRMarket cap: CA$216.6mHealthleadSymbol: SET:HLMarket cap: ฿1.4b가격 이력 및 성과Grey Wolf Health 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$1.7552주 최고가CA$1.8052주 최저가CA$0.97베타0.451개월 변동3.55%3개월 변동31.58%1년 변동80.41%3년 변동94.44%5년 변동-16.00%IPO 이후 변동-30.00%최근 뉴스 및 업데이트Reported Earnings • May 22First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025)First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years.Reported Earnings • Apr 19Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024)Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.공시 • Apr 15Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years.분석 기사 • Jan 31Grey Wolf Animal Health Corp.'s (CVE:WOLF) Share Price Not Quite Adding UpGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...더 많은 업데이트 보기Recent updatesReported Earnings • May 22First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025)First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years.Reported Earnings • Apr 19Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024)Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.공시 • Apr 15Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years.분석 기사 • Jan 31Grey Wolf Animal Health Corp.'s (CVE:WOLF) Share Price Not Quite Adding UpGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...Reported Earnings • Nov 23Third quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.016 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.02 (up from CA$0.016 in 3Q 2024). Revenue: CA$9.34m (up 35% from 3Q 2024). Net income: CA$549.0k (up 9.3% from 3Q 2024). Profit margin: 5.9% (down from 7.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.분석 기사 • Oct 24Grey Wolf Animal Health (CVE:WOLF) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Aug 30Grey Wolf Animal Health Corp.'s (CVE:WOLF) 25% Share Price Surge Not Quite Adding UpDespite an already strong run, Grey Wolf Animal Health Corp. ( CVE:WOLF ) shares have been powering on, with a gain of...Reported Earnings • Aug 25Second quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.019 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.02 (up from CA$0.019 in 2Q 2024). Revenue: CA$9.52m (up 32% from 2Q 2024). Net income: CA$751.2k (up 30% from 2Q 2024). Profit margin: 7.9% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses.분석 기사 • Jul 17If EPS Growth Is Important To You, Grey Wolf Animal Health (CVE:WOLF) Presents An OpportunityFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Jun 14Grey Wolf Animal Health Corp.'s (CVE:WOLF) Price Is Out Of Tune With EarningsGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.10, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 23x in the Consumer Retailing industry in Canada. Total returns to shareholders of 77% over the past year.Reported Earnings • May 23First quarter 2025 earnings released: EPS: CA$0.001 (vs CA$0.004 in 1Q 2024)First quarter 2025 results: EPS: CA$0.001 (down from CA$0.004 in 1Q 2024). Revenue: CA$7.92m (up 31% from 1Q 2024). Net income: CA$27.2k (down 78% from 1Q 2024). Profit margin: 0.3% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses.New Risk • Apr 22New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 6.5% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (CA$32.5m market cap, or US$23.5m).Reported Earnings • Apr 20Full year 2024 earnings released: EPS: CA$0.02 (vs CA$0.02 in FY 2023)Full year 2024 results: EPS: CA$0.02 (in line with FY 2023). Revenue: CA$26.8m (up 5.6% from FY 2023). Net income: CA$704.7k (up 16% from FY 2023). Profit margin: 2.6% (up from 2.4% in FY 2023). The increase in margin was driven by higher revenue.공시 • Apr 14Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025.Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.09, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in Canada. Total loss to shareholders of 41% over the past three years.분석 기사 • Dec 04Investors Still Aren't Entirely Convinced By Grey Wolf Animal Health Corp.'s (CVE:WOLF) Revenues Despite 26% Price JumpGrey Wolf Animal Health Corp. ( CVE:WOLF ) shareholders have had their patience rewarded with a 26% share price jump in...New Risk • Dec 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.5% net profit margin). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (CA$34.9m market cap, or US$24.8m).Reported Earnings • Nov 22Third quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.009 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.02 (up from CA$0.009 in 3Q 2023). Revenue: CA$6.90m (up 5.7% from 3Q 2023). Net income: CA$502.2k (up 78% from 3Q 2023). Profit margin: 7.3% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.New Risk • Nov 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Profit margins are more than 30% lower than last year (2.7% net profit margin). Market cap is less than US$100m (CA$26.4m market cap, or US$18.9m).공시 • Oct 30Grey Wolf Animal Health Announces Launch of SILEOGrey Wolf Animal Health Corp. announced the Canadian commercial launch of SILEO® (dexmedetomidine hydrochloride oromucosal gel) to veterinary clinics throughout Canada. SILEO builds on Grey Wolf's portfolio dedicated to behaviour and anxiety health in companion animals. Dogs that experience fear and anxiety in response to loud noise such as fireworks now have a new treatment option. SILEO is available from veterinarians by prescription and can be administered at home by pet owners to help calm dogs without sedation.분석 기사 • Aug 23These 4 Measures Indicate That Grey Wolf Animal Health (CVE:WOLF) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.006 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.02 (up from CA$0.006 in 2Q 2023). Revenue: CA$7.20m (up 7.7% from 2Q 2023). Net income: CA$577.5k (up 188% from 2Q 2023). Profit margin: 8.0% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue.Buy Or Sell Opportunity • Aug 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to CA$0.61. The fair value is estimated to be CA$0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last year. Meanwhile, the company has become profitable.Reported Earnings • May 24First quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.013 in 1Q 2023)First quarter 2024 results: EPS: CA$0.004 (down from CA$0.013 in 1Q 2023). Revenue: CA$6.05m (flat on 1Q 2023). Net income: CA$126.1k (down 69% from 1Q 2023). Profit margin: 2.1% (down from 6.8% in 1Q 2023).Board Change • May 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Director Rob Harris is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.분석 기사 • Apr 19It's Down 25% But Grey Wolf Animal Health Corp. (CVE:WOLF) Could Be Riskier Than It LooksGrey Wolf Animal Health Corp. ( CVE:WOLF ) shareholders won't be pleased to see that the share price has had a very...Reported Earnings • Apr 12Full year 2023 earnings released: EPS: CA$0.02 (vs CA$0.15 in FY 2022)Full year 2023 results: EPS: CA$0.02 (down from CA$0.15 in FY 2022). Revenue: CA$25.4m (up 12% from FY 2022). Net income: CA$609.6k (down 76% from FY 2022). Profit margin: 2.4% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses.공시 • Apr 12Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024.분석 기사 • Jan 22Grey Wolf Animal Health Corp.'s (CVE:WOLF) Shares Not Telling The Full StoryYou may think that with a price-to-sales (or "P/S") ratio of 1x Grey Wolf Animal Health Corp. ( CVE:WOLF ) is a stock...Reported Earnings • Nov 24Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.078 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0.01 (up from CA$0.078 loss in 3Q 2022). Revenue: CA$6.53m (up 12% from 3Q 2022). Net income: CA$282.5k (up CA$1.43m from 3Q 2022). Profit margin: 4.3% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue.공시 • Nov 02Murray Roach to Leave Grey Wolf Animal Health Corp. as Chief Commercial OfficerGrey Wolf Animal Health Corp. announced that effective October 31, 2023 Murray Roach, Chief Commercial Officer, has decided to leave Grey Wolf.Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.075 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.01 (up from CA$0.075 loss in 2Q 2022). Revenue: CA$6.68m (up 8.8% from 2Q 2022). Net income: CA$200.5k (up CA$1.30m from 2Q 2022). Profit margin: 3.0% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses.Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: CA$0.013 (vs CA$0.072 loss in 1Q 2022)First quarter 2023 results: EPS: CA$0.013 (up from CA$0.072 loss in 1Q 2022). Revenue: CA$6.04m (up 7.0% from 1Q 2022). Net income: CA$410.5k (up CA$1.47m from 1Q 2022). Profit margin: 6.8% (up from net loss in 1Q 2022). The move to profitability was primarily driven by lower expenses.Reported Earnings • Apr 26Full year 2022 earnings releasedFull year 2022 results: Revenue: CA$22.6m (up 73% from FY 2021). Net income: CA$2.54m (up CA$3.51m from FY 2021). Profit margin: 11% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.Reported Earnings • Dec 03Third quarter 2022 earnings releasedThird quarter 2022 results: CA$1.30 loss per share. Net loss: CA$1.14m (flat on 3Q 2021).공시 • Nov 29Grey Wolf Animal Health Corp. Announces Board ChangesGrey Wolf Animal Health Corp. announced that on November 15, 2022, the company completed the previously announced qualifying transaction with Magen Ventures I Inc. In connection with the completion of the qualifying transaction, the Company is also announcing (i) the resignation of Jolyon Burton, and (ii) the appointment of Jill Angevine and Diane Bourassa to Grey Wolf's Board of Directors as independent directors. Ms. Angevine is a finance professional with more than 25 years of experience in the investment management industry including portfolio management, capital markets and equity research. She currently serves as President and CEO of Brownstone Asset Management, a private investment firm, and holds non-executive directorships at additional public companies in the energy and mining sectors. Ms. Angevine holds a Bachelor of Commerce degree from the University of Calgary and has earned the Chartered Public Accountant (CPA, CA), the Chartered Financial Analyst (CFA), and the Institute of Corporate Directors (ICD.D) designations. Ms. Bourassa is a visionary business leader with extensive operational and financial expertise. Throughout her 30-year career, Ms. Bourassa succeeded in developing highly competitive and performing teams. Determined to share her skills and boundless energy with other companies, she has been focused since January 2022 on strategic consulting, individual coaching, and business development services. Ms. Bourassa worked for 14 years in the Canadian subsidiary of Vetoquinol S.A. Her leadership as General Manager of Vetoquinol Canada from 2011 to 2021 propelled Vetoquinol into the top 5 animal health pharmaceutical companies in Canada. Ms. Bourassa was a member of the Board of Directors of the Canadian Animal Health Institute for a period of 10 years, where she held various positions, including Chair of the Board of Directors from 2015 to 2016. Ms. Bourassa started her career at Ernst & Young and holds a CPA, CA designation.Board Change • Nov 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Director & CVMO Ian Sandler was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률WOLFCA Consumer RetailingCA 시장7D-2.2%4.9%-1.0%1Y80.4%15.5%28.9%전체 주주 수익률 보기수익률 대 산업: WOLF은 지난 1년 동안 15.5%의 수익을 기록한 Canadian Consumer Retailing 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: WOLF은 지난 1년 동안 28.9%를 기록한 Canadian 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is WOLF's price volatile compared to industry and market?WOLF volatilityWOLF Average Weekly Movement9.1%Consumer Retailing Industry Average Movement4.2%Market Average Movement9.7%10% most volatile stocks in CA Market16.6%10% least volatile stocks in CA Market3.7%안정적인 주가: WOLF는 지난 3개월 동안 Canadian 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: WOLF의 주간 변동성(9%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트n/an/aAngela Cechettogreywolfah.com는 캐나다에서 동물 건강 및 웰니스 회사로 운영되고 있습니다. 이 회사는 동물 건강 사업 부문과 약국 사업 부문의 두 부문으로 운영됩니다. 이 회사는 동물병원을 대상으로 의약품, 건강기능식품, 소모품의 판매, 마케팅, 유통을 담당합니다.더 보기Grey Wolf Health Corp. 기초 지표 요약Grey Wolf Health의 순이익과 매출은 시가총액과 어떻게 비교됩니까?WOLF 기초 통계시가총액CA$60.36m순이익 (TTM)CA$1.77m매출 (TTM)CA$36.60m34.0x주가수익비율(P/E)1.6x주가매출비율(P/S)WOLF는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표WOLF 손익계산서 (TTM)매출CA$36.60m매출원가CA$16.97m총이익CA$19.63m기타 비용CA$17.85m순이익CA$1.77m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)0.051총이익률53.63%순이익률4.85%부채/자본 비율79.4%WOLF의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/30 00:46종가2026/06/30 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Grey Wolf Health Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • May 22First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025)First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years.
Reported Earnings • Apr 19Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024)Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
공시 • Apr 15Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years.
분석 기사 • Jan 31Grey Wolf Animal Health Corp.'s (CVE:WOLF) Share Price Not Quite Adding UpGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...
Reported Earnings • May 22First quarter 2026 earnings released: EPS: CA$0.004 (vs CA$0.001 in 1Q 2025)First quarter 2026 results: EPS: CA$0.004 (up from CA$0.001 in 1Q 2025). Revenue: CA$8.75m (up 11% from 1Q 2025). Net income: CA$145.3k (up 433% from 1Q 2025). Profit margin: 1.7% (up from 0.3% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 114 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CA$1.75, the stock trades at a trailing P/E ratio of 36.1x. Average trailing P/E is 24x in the Consumer Retailing industry in Canada. Total returns to shareholders of 157% over the past three years.
Reported Earnings • Apr 19Full year 2025 earnings released: EPS: CA$0.05 (vs CA$0.023 in FY 2024)Full year 2025 results: EPS: CA$0.05 (up from CA$0.023 in FY 2024). Revenue: CA$35.8m (up 33% from FY 2024). Net income: CA$1.66m (up 135% from FY 2024). Profit margin: 4.6% (up from 2.6% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
공시 • Apr 15Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026Grey Wolf Animal Health Corp., Annual General Meeting, Jun 24, 2026.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CA$1.50, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 22x in the Consumer Retailing industry in Canada. Total returns to shareholders of 83% over the past three years.
분석 기사 • Jan 31Grey Wolf Animal Health Corp.'s (CVE:WOLF) Share Price Not Quite Adding UpGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...
Reported Earnings • Nov 23Third quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.016 in 3Q 2024)Third quarter 2025 results: EPS: CA$0.02 (up from CA$0.016 in 3Q 2024). Revenue: CA$9.34m (up 35% from 3Q 2024). Net income: CA$549.0k (up 9.3% from 3Q 2024). Profit margin: 5.9% (down from 7.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
분석 기사 • Oct 24Grey Wolf Animal Health (CVE:WOLF) Has A Pretty Healthy Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • Aug 30Grey Wolf Animal Health Corp.'s (CVE:WOLF) 25% Share Price Surge Not Quite Adding UpDespite an already strong run, Grey Wolf Animal Health Corp. ( CVE:WOLF ) shares have been powering on, with a gain of...
Reported Earnings • Aug 25Second quarter 2025 earnings released: EPS: CA$0.02 (vs CA$0.019 in 2Q 2024)Second quarter 2025 results: EPS: CA$0.02 (up from CA$0.019 in 2Q 2024). Revenue: CA$9.52m (up 32% from 2Q 2024). Net income: CA$751.2k (up 30% from 2Q 2024). Profit margin: 7.9% (down from 8.0% in 2Q 2024). The decrease in margin was driven by higher expenses.
분석 기사 • Jul 17If EPS Growth Is Important To You, Grey Wolf Animal Health (CVE:WOLF) Presents An OpportunityFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
분석 기사 • Jun 14Grey Wolf Animal Health Corp.'s (CVE:WOLF) Price Is Out Of Tune With EarningsGrey Wolf Animal Health Corp.'s ( CVE:WOLF ) price-to-earnings (or "P/E") ratio of 62.1x might make it look like a...
Valuation Update With 7 Day Price Move • Jun 13Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.10, the stock trades at a trailing P/E ratio of 62.1x. Average trailing P/E is 23x in the Consumer Retailing industry in Canada. Total returns to shareholders of 77% over the past year.
Reported Earnings • May 23First quarter 2025 earnings released: EPS: CA$0.001 (vs CA$0.004 in 1Q 2024)First quarter 2025 results: EPS: CA$0.001 (down from CA$0.004 in 1Q 2024). Revenue: CA$7.92m (up 31% from 1Q 2024). Net income: CA$27.2k (down 78% from 1Q 2024). Profit margin: 0.3% (down from 2.1% in 1Q 2024). The decrease in margin was driven by higher expenses.
New Risk • Apr 22New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 6.5% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (6.5% operating cash flow to total debt). Minor Risk Market cap is less than US$100m (CA$32.5m market cap, or US$23.5m).
Reported Earnings • Apr 20Full year 2024 earnings released: EPS: CA$0.02 (vs CA$0.02 in FY 2023)Full year 2024 results: EPS: CA$0.02 (in line with FY 2023). Revenue: CA$26.8m (up 5.6% from FY 2023). Net income: CA$704.7k (up 16% from FY 2023). Profit margin: 2.6% (up from 2.4% in FY 2023). The increase in margin was driven by higher revenue.
공시 • Apr 14Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2025.
Valuation Update With 7 Day Price Move • Dec 05Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.09, the stock trades at a trailing P/E ratio of 40.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in Canada. Total loss to shareholders of 41% over the past three years.
분석 기사 • Dec 04Investors Still Aren't Entirely Convinced By Grey Wolf Animal Health Corp.'s (CVE:WOLF) Revenues Despite 26% Price JumpGrey Wolf Animal Health Corp. ( CVE:WOLF ) shareholders have had their patience rewarded with a 26% share price jump in...
New Risk • Dec 03New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (3.5% net profit margin). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (CA$34.9m market cap, or US$24.8m).
Reported Earnings • Nov 22Third quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.009 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.02 (up from CA$0.009 in 3Q 2023). Revenue: CA$6.90m (up 5.7% from 3Q 2023). Net income: CA$502.2k (up 78% from 3Q 2023). Profit margin: 7.3% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
New Risk • Nov 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Profit margins are more than 30% lower than last year (2.7% net profit margin). Market cap is less than US$100m (CA$26.4m market cap, or US$18.9m).
공시 • Oct 30Grey Wolf Animal Health Announces Launch of SILEOGrey Wolf Animal Health Corp. announced the Canadian commercial launch of SILEO® (dexmedetomidine hydrochloride oromucosal gel) to veterinary clinics throughout Canada. SILEO builds on Grey Wolf's portfolio dedicated to behaviour and anxiety health in companion animals. Dogs that experience fear and anxiety in response to loud noise such as fireworks now have a new treatment option. SILEO is available from veterinarians by prescription and can be administered at home by pet owners to help calm dogs without sedation.
분석 기사 • Aug 23These 4 Measures Indicate That Grey Wolf Animal Health (CVE:WOLF) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Aug 22Second quarter 2024 earnings released: EPS: CA$0.02 (vs CA$0.006 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.02 (up from CA$0.006 in 2Q 2023). Revenue: CA$7.20m (up 7.7% from 2Q 2023). Net income: CA$577.5k (up 188% from 2Q 2023). Profit margin: 8.0% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue.
Buy Or Sell Opportunity • Aug 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to CA$0.61. The fair value is estimated to be CA$0.77, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.0% over the last year. Meanwhile, the company has become profitable.
Reported Earnings • May 24First quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.013 in 1Q 2023)First quarter 2024 results: EPS: CA$0.004 (down from CA$0.013 in 1Q 2023). Revenue: CA$6.05m (flat on 1Q 2023). Net income: CA$126.1k (down 69% from 1Q 2023). Profit margin: 2.1% (down from 6.8% in 1Q 2023).
Board Change • May 21High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Independent Director Rob Harris is the most experienced director on the board, commencing their role in 2016. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
분석 기사 • Apr 19It's Down 25% But Grey Wolf Animal Health Corp. (CVE:WOLF) Could Be Riskier Than It LooksGrey Wolf Animal Health Corp. ( CVE:WOLF ) shareholders won't be pleased to see that the share price has had a very...
Reported Earnings • Apr 12Full year 2023 earnings released: EPS: CA$0.02 (vs CA$0.15 in FY 2022)Full year 2023 results: EPS: CA$0.02 (down from CA$0.15 in FY 2022). Revenue: CA$25.4m (up 12% from FY 2022). Net income: CA$609.6k (down 76% from FY 2022). Profit margin: 2.4% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses.
공시 • Apr 12Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024Grey Wolf Animal Health Corp., Annual General Meeting, Jun 19, 2024.
분석 기사 • Jan 22Grey Wolf Animal Health Corp.'s (CVE:WOLF) Shares Not Telling The Full StoryYou may think that with a price-to-sales (or "P/S") ratio of 1x Grey Wolf Animal Health Corp. ( CVE:WOLF ) is a stock...
Reported Earnings • Nov 24Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.078 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0.01 (up from CA$0.078 loss in 3Q 2022). Revenue: CA$6.53m (up 12% from 3Q 2022). Net income: CA$282.5k (up CA$1.43m from 3Q 2022). Profit margin: 4.3% (up from net loss in 3Q 2022). The move to profitability was primarily driven by higher revenue.
공시 • Nov 02Murray Roach to Leave Grey Wolf Animal Health Corp. as Chief Commercial OfficerGrey Wolf Animal Health Corp. announced that effective October 31, 2023 Murray Roach, Chief Commercial Officer, has decided to leave Grey Wolf.
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.075 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.01 (up from CA$0.075 loss in 2Q 2022). Revenue: CA$6.68m (up 8.8% from 2Q 2022). Net income: CA$200.5k (up CA$1.30m from 2Q 2022). Profit margin: 3.0% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses.
Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: CA$0.013 (vs CA$0.072 loss in 1Q 2022)First quarter 2023 results: EPS: CA$0.013 (up from CA$0.072 loss in 1Q 2022). Revenue: CA$6.04m (up 7.0% from 1Q 2022). Net income: CA$410.5k (up CA$1.47m from 1Q 2022). Profit margin: 6.8% (up from net loss in 1Q 2022). The move to profitability was primarily driven by lower expenses.
Reported Earnings • Apr 26Full year 2022 earnings releasedFull year 2022 results: Revenue: CA$22.6m (up 73% from FY 2021). Net income: CA$2.54m (up CA$3.51m from FY 2021). Profit margin: 11% (up from net loss in FY 2021). The move to profitability was driven by higher revenue.
Reported Earnings • Dec 03Third quarter 2022 earnings releasedThird quarter 2022 results: CA$1.30 loss per share. Net loss: CA$1.14m (flat on 3Q 2021).
공시 • Nov 29Grey Wolf Animal Health Corp. Announces Board ChangesGrey Wolf Animal Health Corp. announced that on November 15, 2022, the company completed the previously announced qualifying transaction with Magen Ventures I Inc. In connection with the completion of the qualifying transaction, the Company is also announcing (i) the resignation of Jolyon Burton, and (ii) the appointment of Jill Angevine and Diane Bourassa to Grey Wolf's Board of Directors as independent directors. Ms. Angevine is a finance professional with more than 25 years of experience in the investment management industry including portfolio management, capital markets and equity research. She currently serves as President and CEO of Brownstone Asset Management, a private investment firm, and holds non-executive directorships at additional public companies in the energy and mining sectors. Ms. Angevine holds a Bachelor of Commerce degree from the University of Calgary and has earned the Chartered Public Accountant (CPA, CA), the Chartered Financial Analyst (CFA), and the Institute of Corporate Directors (ICD.D) designations. Ms. Bourassa is a visionary business leader with extensive operational and financial expertise. Throughout her 30-year career, Ms. Bourassa succeeded in developing highly competitive and performing teams. Determined to share her skills and boundless energy with other companies, she has been focused since January 2022 on strategic consulting, individual coaching, and business development services. Ms. Bourassa worked for 14 years in the Canadian subsidiary of Vetoquinol S.A. Her leadership as General Manager of Vetoquinol Canada from 2011 to 2021 propelled Vetoquinol into the top 5 animal health pharmaceutical companies in Canada. Ms. Bourassa was a member of the Board of Directors of the Canadian Animal Health Institute for a period of 10 years, where she held various positions, including Chair of the Board of Directors from 2015 to 2016. Ms. Bourassa started her career at Ernst & Young and holds a CPA, CA designation.
Board Change • Nov 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Founder, Director & CVMO Ian Sandler was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
